AI-enabled validation reduces manual work, meets faster timelines, delivers consistency and better audit readiness — all while meeting regulatory requirements.
- 88 results
- Reset filters
Loading...
Explore how OBBBA is reshaping US healthcare as it relates to coverage, funding, and pharma strategy in this breakdown with PwC health leaders.
PwC and Google Cloud helped a healthcare provider use AI to unify data, improving cancer care, clinical trial matching and saving $50M+ annually.
Help guide providers, payers, pharma companies and employers as they determine medical cost trends and the factors driving or dampening spending in 2026.
PwC specialists unpack how regulatory changes, pricing pressures, and global innovation are influencing pharma and health services M&A—and what companies should do now to reassess pricing strategies, stabilize supply chains, and navigate policy risk.
Rewire your pharma supply chain strategy with three decisive actions you can take now—while navigating shifting policy landscapes and geopolitical changes.
How the One Big Beautiful Bill reshapes US healthcare and what providers, payors, PBMs and pharma should do to respond to policy, funding and coverage shifts.
Companies are responding with targeted mitigation strategies, while maintaining flexibility as tariff policies continue to evolve.
Health services M&A has weathered a complicated macroeconomic and political environment but, strong subsector growth demonstrates sector durability.
The health industries quarterly offers insights on accounting and reporting hot topics impacting the industry.
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
This publication highlights industry-specific factors to be considered and provides guidance on the most pertinent accounting solutions for the pharmaceutical, life sciences and medical device industry.
Loading...
Our insights. Your choices.
Subscribe to industry and sector insights
Follow us
